About US
Contact us
-
J&J stands by sales growth ambitions—and points to potential Tremfya boon—as Stelara biosimilars take holdAs Stelara biosimilars chip away at sales in Europe and off-brand rivals start to grace the stage in the U.S., Johnson & Johnson is confident it can eke out revenue growth this year despite the s2025/1/16
-
Johnson & Johnson's Spravato gains FDA nod to be used as a monotherapyAlready on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the FDA hasblessedthe nasal spray to be used as a monotherapy for major dep2025/1/14
-
Sanofi API plant hit with FDA warning letter detailing quality, consistency flubsDespite receiving a prior wrist slap from the FDA in the shape of a Form 483, Sanofi is still working to right the ship at a U.S. drug ingredients plant tied to its longstanding subsidiary Genzyme. T2025/1/14
-
Large study of Novo, Lilly weight loss drugs shows decrease in risk of Alzheimer'sAs evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has approved Novo Nordisk’s semaglutide for heart disease and Eli Lilly’s tirzepatide2025/1/9
-
Sage sues Biogen as analyst detects little interest in buyout at original offer priceSage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience partner. The lawsuit is sealed in Delaware’s Court of Chancery, but in a se2025/1/9
-
Citius Oncology weighs strategic options on road to launching newly-approved lymphoma medAfter nabbing an FDA approval last summer for its T-cell lymphoma treatment Lymphir, Citius Oncology is eyeing strategic alternatives. The company, a subsidiary of Citius Pharmaceuticals, is explorin2025/1/7
-
Novo asks FDA to restrict Victoza compounding amid GLP-1 outsourcing rowAs concerns around knockoffs of newer GLP-1 drugs like Ozempic and Wegovy take center stage, Novo Nordisk’s efforts to ward off competition against its aging diabetes blockbuster Victoza have been qu2025/1/7
-
2025 forecast: After Novo, Lilly expansion sprees, 'positive signals' emerge around future supply of GLP-1 drugsWhile the recent launches of GLP-1 drugs from Novo Nordisk and Eli Lilly have been nothing short of a staggering financial success, the rollouts have consistently been hamstrung by manufacturing and2025/1/2
-
Roche projected to claim pharma's 2025 sales crown as Novo, Lilly climb rankings: EvaluateThe story of Eli Lilly and Novo Nordisk’s GLP-1 dominance is likely to play out again in 2025 as the metabolic medicine rivals continue to smooth over supply issues and rake in dividends from their r2025/1/2
-
Lilly looks to 'protect its interests' by moving to join FDA lawsuit over compounded tirzepatideAfter plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking to protect its investment by wading into a lawsuit that seeks to allow co2024/12/31